Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS
- Conditions
- ALS
- Registration Number
- NCT06743776
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The purpose of this Expanded Access Program is to provide MN-166 (ibudilast) to ALS patients who are not eligible for an enrolling ALS clinical trial. This Expanded Access Program will assess if MN-166 can help people with ALS in slowing down the progression of the disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of ibudilast relate to neuroinflammation and neuroprotection in ALS pathogenesis?
How does ibudilast compare to Riluzole/Edaravone in slowing ALS progression via neurofilament light chain (NfL) biomarker analysis?
Which ALS subtypes (e.g., TDP-43, C9ORF72) show differential response to ibudilast based on NfL and other biomarkers?
What adverse event profiles are associated with long-term ibudilast use in ALS patients under expanded access programs?
Are there synergistic combination therapies involving ibudilast and AMX0035/TUDCA for ALS treatment in clinical development?
Trial Locations
- Locations (1)
Mayo Clinic
πΊπΈRochester, Minnesota, United States
Mayo ClinicπΊπΈRochester, Minnesota, United StatesAlissa BojkoContactbojko.alissa@mayo.eduStephen Johnson, MDPrincipal InvestigatorColette McHugh-StrongContactmchugh-strong.colette@mayo.eduBjorn Oskarsson, MDPrincipal InvestigatorJeff LaivellContactlaivell.jeffrey@mayo.eduNathan Staff, MD, PhDPrincipal Investigator